Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's Soticlestat?
Soticlestat is a small molecule commercialized by Takeda Pharmaceutical, with a leading Phase III program in Dravet Syndrome (Severe Myoclonic...
Soticlestat by Takeda Pharmaceutical for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Soticlestat is under clinical development by Takeda Pharmaceutical and currently in Phase III for Dravet Syndrome (Severe Myoclonic Epilepsy of...
Soticlestat by Takeda Pharmaceutical for Lennox-Gastaut Syndrome: Likelihood of Approval
Soticlestat is under clinical development by Takeda Pharmaceutical and currently in Phase III for Lennox-Gastaut Syndrome. According to GlobalData, Phase...